Treatment of psoriasis with etanercept in immunocompromised patients: Two case reports

Tumour necrosis factor (TNF)-α blocking agents have revolutionized the treatment of psoriasis and psoriatic arthritis. Concerns remain about increased susceptibility to infection and onset of malignancies, and the use of TNF-α agents in patients with HIV infection or undergoing immunosuppressant tre...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of international medical research Jg. 44; H. 1_suppl; S. 67 - 71
Hauptverfasser: De Simone, Clara, Perino, Francesca, Caldarola, Giacomo, D’Agostino, Magda, Peris, Ketty
Format: Journal Article
Sprache:Englisch
Veröffentlicht: London, England SAGE Publications 01.09.2016
Schlagworte:
Immuno-Mediated Diseases And Comorbities
Antitumour necrosis factor-α agents
psoriatic arthritis
comorbidities
etanercept
psoriasis
ISSN:0300-0605, 1473-2300, 1473-2300
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Tumour necrosis factor (TNF)-α blocking agents have revolutionized the treatment of psoriasis and psoriatic arthritis. Concerns remain about increased susceptibility to infection and onset of malignancies, and the use of TNF-α agents in patients with HIV infection or undergoing immunosuppressant treatment is debated. We report cases of severe plaque psoriasis in a patient with HIV infection and in a liver transplant recipient who were successfully treated with etanercept, an anti-TNF-α agent, without notable side-effects.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0300-0605
1473-2300
1473-2300
DOI:10.1177/0300060515593250